Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA 30341, USA.
J Microencapsul. 2009 Sep;26(6):493-500. doi: 10.1080/02652040802465719.
Parenteral route is preferred for low molecular weight heparin (LMWH) due to poor oral bioavailability. Biodegradable formulation components were evaluated for possible interactions between the physical mixtures using differential scanning calorimetry. LMWH and an absorption enhancer papain were encapsulated in bovine serum albumin matrix and four formulations were spray-dried (MS.1, MS.2, MS.3, MS.4). Formulations were evaluated for product yield, particle size, particle charge and encapsulation efficiency. In vitro release assessed in pH 7.2 phosphate buffer saline (PBS) revealed a burst release effect (60%) for all the formulations except MS.1. In vivo studies performed in male Sprague Dawley rats showed an enhancement in drug absorption for the MS.2 and MS.3 formulations because of papain action on paracellular tight junctions. A significant increase in LMWH oral bioavailability was demonstrated by MS.3 (21%), among the formulations encapsulated with papain.
由于低分子肝素 (LMWH) 的口服生物利用度较差,因此优选肠外途径给药。使用差示扫描量热法评估可生物降解制剂成分在物理混合物之间可能发生的相互作用。将 LMWH 和吸收增强剂木瓜蛋白酶包封在牛血清白蛋白基质中,并对四种制剂进行喷雾干燥(MS.1、MS.2、MS.3、MS.4)。对产物收率、粒径、颗粒电荷和包封效率进行评价。在 pH 7.2 的磷酸盐缓冲盐水 (PBS) 中进行的体外释放研究表明,除 MS.1 外,所有制剂均出现突释效应(60%)。在雄性 Sprague Dawley 大鼠中的体内研究表明,由于木瓜蛋白酶对细胞旁紧密连接的作用,MS.2 和 MS.3 制剂增强了药物吸收。与用木瓜蛋白酶包封的其他制剂相比,MS.3(21%)显著提高了 LMWH 的口服生物利用度。